文献速递药物不良反应与药物警戒

评估药物警戒活动对健康的影响:四个安全信号示例

Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals.
PubMed 文献 · Drug Saf · 2021-02-19

该研究利用荷兰公开数据,评估四个产品特定安全信号的药物警戒活动对公共健康的影响。研究采用评估支持工具,发现仅CPA/EE和培高利特信号可在不同假设下进行粗略影响估算,并强调评估方法学挑战与数据需求。

要点

  • 四个安全信号中仅两个可粗略估算影响,其余受数据限制。
  • 评估支持工具可指导药物警戒影响评估所需数据元素与步骤。
  • 产品特定安全信号的影响评估存在方法学挑战。

核心结论

  • 药物警戒活动对公共健康的影响评估存在方法学挑战和数据需求。
  • 结构化评估支持工具可在数据可用时指导影响测量或估算。

研究设计与样本

  • 利用荷兰公开数据,采用评估支持工具评估四个产品特定安全信号。

主要发现

  • CPA/EE和培高利特信号可基于文献风险与利用数据进行粗略影响估算。
  • 其余两个信号的影响未能估算。

临床怎么用

  • 临床药学智能体可参考评估支持工具梳理药物警戒影响评估所需数据元素。

局限性

  • 评估依赖公开数据,部分信号数据不足。
  • 粗略估算需基于不同程度假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The impact of pharmacovigilance activities on public health remains under-investigated, and measuring the impact on health of pharmacovigilance activities for a specific safety signal is challenging. OBJECTIVE: To gain more insight into the methodological challenges and the data required, we assessed the impact of pharmacovigilance on public health for four identified product-specific safety signals using publicly available data in the Netherlands. The assessment was on the impact of the intertwined and complementary steps of the pharmacovigilance pathways. METHODS: The impact of pharmacovigilance on public health was assessed using the assessment support tool and 'open data' from the Netherlands for four different types of pharmacovigilance safety signals: (1) off-label use of cyproterone acetate/ethinyloestradiol (CPA/EE) and thrombotic risk after pharmacovigilance measures after 2014; (2) pergolide and the risk of cardiac valvulopathy after pharmacovigilance activities in 2003; (3) proton pump inhibitors and the risk of hypomagnesaemia after pharmacovigilance activities in 2011; (4) rosiglitazone withdrawal from the market because of cardiovascular effects in 2010. RESULTS: For the signals on CPA/EE and pergolide, a crude estimation of the impact could be made with varying degrees of assumptions based on the risk described in the literature and utilisation data. CONCLUSION: This article highlights the methodological challenges and the data required to assess the impact of product-specific safety signals. A structured assessment support tool can be used as a guide for the necessary data elements and steps needed for the measurement or estimation of impact of pharmacovigilance activities on public health, provided that the appropriate data are available.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. van Hunsel F, Peters L, Gardarsdottir H, et al. Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals. Drug Saf. 2021. PMID: 33606201. doi:10.1007/s40264-021-01047-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。